This report takes a closer look at QuidelOrtho Corp. (QDEL). The company is navigating a shift in its revenue mix, with COVID-19 testing declining but core diagnostic segments showing resilience. Recent FDA clearance for its cardiac assay adds a new catalyst to watch as investors assess its financial guidance and market performance.
Recent Developments
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com